Silverback Therapeutics, Inc. (SBTX) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Product
02M5M8M10M12M15M18M20MQ1 2025Q2 2025

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
050M100M150M200M250M300M350M400MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
02505007501K1K2K2K2KQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
010M20M30M40M50M60M70M80MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

EBITDA

EBITDA
-60M-45M-30M-15M015M30M45M60MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

EPS

EPSEPS Diluted
000111222Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Revenue Variation (%)

Revenue Variation
-2004501K2K2K3K4K4K5KQ3 2024Q4 2024Q1 2025Q2 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-400K-349K-298K-247K-196K-145K-94K-43K8KQ2 2024Q3 2024Q4 2024Q2 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
02K5K8K10K12K15K18K20KQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Price-to-Earning Ratio

P/E Ratio
-30-26-21-16-12-8-326Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
025M50M75M100M125M150M175M200MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
001122233Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
048111519222630Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025
💰 Cash Flow Statement

Operating Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
012M25M38M50M62M75M88M100MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Free Cash Flow

Cash At End Of Period
08M15M22M30M38M45M52M60MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
025M50M75M100M125M150M175M200MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025
🏦 Balance Sheet
📈 Key Metrics